InnoCare Pharma (HKG:9969, SHA:688428) posted 409.3 million yuan in net profit attributable to shareholders of the listed company for the third quarter, compared with an attributable net loss a year ago.
The pharmaceutical company's Hong Kong and Shanghai shares both fell 2% during Tuesday's afternoon trade.
EPS was 0.24 yuan, a Monday filing with the Hong Kong Stock Exchange showed.
For the three months ended Sept. 30, operating revenue was 962 million yuan, up 151% from a year ago, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments